PR
VRDN icon

PSP Research’s Viridian Therapeutics VRDN Stock Holding History

PSP Research’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,967
Closed -$528K – 100
2025
Q4 		$528K Buy
+16,967
New +$465K 0.46% 48

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PSP Research's VRDN Position: Q1 2026 in Review

PSP Research sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 16,967 shares — an estimated $528K sold.

PSP Research first reported a position in VRDN in Q4 2025 and held it in 1 quarter. The position peaked at $528K in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • PSP Research reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • PSP Research sold 16,967 Viridian Therapeutics shares in Q1 2026, an estimated $528K.
  • PSP Research first reported a position in Viridian Therapeutics in Q4 2025 and held it in 1 quarter.
  • PSP Research's Viridian Therapeutics position peaked at $528K in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on PSP Research's 13F filing for Q1 2026, filed 17 Apr 2026.